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Abstract Cervical cancer, the most common cancer affecting women in developing countries, is caused by persistent infection 
with “high-risk” genotypes of human papillomaviruses (HPV). The most common oncogenic HPV genotypes are 16 and 18, causing 
approximately 70% of all cervical cancers. Types 6 and 11 do not contribute to the incidence of high-grade dysplasias (precancerous 
lesions) or cervical cancer, but do cause laryngeal papillomas and most genital warts. HPV is highly transmissible, with peak incidence 
soon after the onset of sexual activity.
A quadrivalent (types 6, 11, 16 and 18) HPV vaccine has recently been licensed in several countries following the determination 
that it has an acceptable benefit/risk profile. In large phase III trials, the vaccine prevented 100% of moderate and severe precancerous 
cervical lesions associated with types 16 or 18 among women with no previous infection with these types. A bivalent (types 16 and 
18) vaccine has also undergone extensive evaluation and been licensed in at least one country. Both vaccines are prepared from 
non-infectious, DNA-free virus-like particles produced by recombinant technology and combined with an adjuvant. With three doses 
administered, they induce high levels of serum antibodies in virtually all vaccinated individuals. In women who have no evidence 
of past or current infection with the HPV genotypes in the vaccine, both vaccines show > 90% protection against persistent HPV 
infection for up to 5 years after vaccination, which is the longest reported follow-up so far. Vaccinating at an age before females are 
exposed to HPV would have the greatest impact. Since HPV vaccines do not eliminate the risk of cervical cancer, cervical screening will 
still be required to minimize cancer incidence. Tiered pricing for HPV vaccines, innovative financing mechanisms and multidisciplinary 
partnerships will be essential in order for the vaccines to reach populations in greatest need.
Bulletin of the World Health Organization 2007;85:719–726.
Une traduction en français de ce résumé figure à la fin de l’article. Al final del artículo se facilita una traducción al español.
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Introduction
Cervical cancer is estimated to affect ap-
proximately 500 000 women each year, 
of whom 80% live in developing coun-
tries. Virtually all cervical cancer cases re-
sult from genital infection with human 
papillomavirus (HPV). Well-organized 
programmes of regular gynaecological 
screening and treatment of precancer-
ous lesions have been very effective in 
preventing squamous cervical cancer 
(the most common kind) but have had 
less impact on adenocarcinoma1 and are 
difficult to implement in low-resource 
settings. In 2006, a quadrivalent vaccine 
was licensed in several countries, and 
a bivalent vaccine has recently been li-
censed in Australia. Countries will need 
to consider whether and how to use 
these new vaccines. This document 
provides an overview of key informa-
tion on HPV and HPV vaccines for 
policy-makers. It is based on a longer 
document (“Human Papillomavirus 
and HPV vaccines: technical informa-
tion for policy-makers and health pro-
fessionals”) that has been reviewed by an 
international group of experts, available 
online at: http://www.who.int/vaccines-
documents/DocsPDF07/866.pdf.
HPV and cancers
Human papillomaviruses are DNA vi-
ruses that infect basal epithelial (skin 
or mucosal) cells. There is international 
consensus that “high-risk” genotypes, 
including genotypes 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59 and 66, can 
lead to cervical cancer 2 and are associ-
ated with other mucosal anogenital and 
head and neck cancers. Infections with 
other genotypes, termed “low-risk,” can 
cause benign or low-grade cervical tissue 
changes and genital warts (condyloma 
acuminata), which are growths on the 
cervix, vagina, vulva and anus in women 
and the penis, scrotum or anus in men. 
They also cause epithelial growths over 
the vocal cords of children and adults 
(juvenile respiratory papillomatosis or 
recurrent respiratory papillomatosis) 
that require surgical intervention.
Most HPV infections of the cervix 
are asymptomatic and more than 90% 
of detected infections are cleared within 
2 years.3 The degree of protection and 
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duration of immunity after natural in-
fection are not known. Only 50–60% 
of women develop serum antibodies to 
HPV after natural infection.4
Early HPV infections may be ac-
companied by mild changes in the epi-
thelium that are detectable by screening 
using virological and/or cytological tech-
niques, allowing early treatment. Cyto-
logical examination of cervical smears 
can detect abnormal growth of squa-
mous cells called squamous intraepi-
thelial lesions (SIL) of low or high 
grade, depending on how much of the 
cervical epithelium is affected and how 
abnormal the cells appear. Cervical in-
traepithelial neoplasia (CIN) is a term 
for abnormal cells in the cervix that are 
detected by histological examination 
of cervical biopsies; grades from 1 to 3 
are used to describe the proportion of 
the thickness of the cervical epithelium 
composed of abnormal cells seen in 
the histology section. In CIN 3, ab-
normal cells span greater than 2/3s of 
the cervical epithelium.  Similar grad-
ings exist for vaginal (VaIN 1–3) and 
vulvar (VIN 1–3) lesions. As the viral 
infection persists, it integrates into the 
human DNA and can lead to cancer 
precursors: moderate or severe cervical 
intra-epithelial neoplasia (CIN 2, CIN 3 
or adenocarcinoma in situ (AIS), often 
grouped together as CIN 2/3 or AIS). If 
these remain untreated, they have a high 
chance of leading to cancer.5
The main burden of HPV-related 
disease is due to cervical cancer. HPV 
was estimated to cause 100% of the 
almost 260 000 deaths from cervical 
cancer worldwide in 2005 (http://www.
who.int/healthinfo/statistics/bodprojec-
tions2030/en/index.html). About 80% 
of cancer cases attributable to HPV were 
in developing countries (Table 1).
The highest estimated incidence 
rates are in sub-Saharan Africa, Mela-
nesia, Latin America and the Caribbean, 
south-central Asia and south-east Asia.
In the most developed countries, 
the primary economic burden of HPV 
disease is related to the early detection 
and management of precancerous le-
sions.6 Not all developed countries have 
successfully controlled their cervical 
cancer burden through screening and 
early treatment programmes.7
The epidemiology of HPV 
infection
There have been many studies world-
wide on the proportion of cervical 
cancer, high- and low-grade squamons 
interaepithelial lesions (HSIL and LSIL) 
due to different HPV genotypes,8–12 but 
there are some gaps in Central Asia, 
Africa and Eastern Europe. With the 
possible exception of Europe, the same 
eight HPV genotypes were the most 
frequent in each region. The relative 
observed prevalence of HPV genotypes 
31, 33, 35, 45, 52 and 58 differed by 
region. These types cause a much lower 
proportion of all HPV infections and 
low-grade cervical lesions. For example, 
in a recent meta-analysis of HPV type 
distribution among women with LSIL, 
among 5910 HPV-positive LSIL lesions; 
the most common types were HPV 16 
(26%), 31 (12%), 51 (11%), 53 (10%), 
56 (10%), 52 (9%), 18 (9%), 66 (9%), 
and 58 (8%). Many other HPV types 
were also detected and multiple infec-
tions were frequent.13
Genital HPV infection is primarily 
transmitted by genital skin-to-skin con-
tact, usually but not necessarily during 
sexual intercourse.14–16 HPV infection 
can occur at any age and has been re-
ported in healthy young children.17 In 
a cross-sectional study of nearly 20 000 
women aged 15–74 years without cer-
vical lesions,18 age-standardized HPV 
prevalence varied more than 10-fold 
between populations. There is an in-
verse relationship between age and hu-
man papillomavirus (HPV) prevalence 
in many countries, but in some of the 
poorest areas studied HPV prevalence 
was high across all age groups.18 In some 
countries, cross-sectional and cohort 
studies have shown a U-shaped curve 
with a first peak in women under 30 
years of age and a second peak in women 
aged 55–64 years.14
Among women infected with HIV, 
a recent meta-analysis found that almost 
40% of those with no cervical cytologi-
cal abnormalities had HPV infection.19 
Simultaneous infection with multiple 
HPV genotypes is more common in 
HIV-infected women than in women 
without HIV. HIV-infected men and 
women are at increased risk of HPV-
associated anal cancer.20
HPV infection risk is associated 
with the number of sex partners that 
the woman or her partner has had over 
a lifetime and recently.21–23 Although 
some cross-sectional studies found no 
evidence of a reduction in HPV preva-
lence through condom use,23–25 lower 
HPV prevalence has been reported 
among women using condoms with 
their regular partners26 and a longitudi-
nal study found that consistent condom 
use protected American college students 
significantly against new HPV infections 
and appeared to protect against CIN le-
sion development.27 A protective effect 
against HPV infection and cervical can-
cer incidence has also been reported for 
women with circumcised partners.28
HPV vaccines
HPV vaccines are prepared from empty 
protein shells called virus-like particles 
Table 1. HPV-infection attributable cancer in 2002: developed and developing countries
Site Attributable to HPV (%) Developed countries Developing countries
Total cancers Attributable to HPV Total cancers Attributable to HPV
Cervix 100 83 400 83 400 409 400 409 400
Penis 40 5 200 2 100 21 100 8 400
Vulva, vagina 40 18 300 7 300 21 700 8 700
Anus 90 14 500 13 100 15 900 14 300
Mouth > = 3 91 200 2 700 183 100 5 500
Oro-pharynx > = 12 24 400 2 900 27 700 3 300
All cancers 5 5 016 100 111 500 5 827 500 449 600
Adapted from: Parkin et al.,7 with permission from Elsevier Sciences.
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Table 2. Characteristics of two candidate HPV vaccines and trial populations
Manufacturer and trade name Quadrivalent vaccine Bivalent vaccine
Merck [Gardasil] GlaxoSmithKline [Cervarix]
Virus-like particles [VLPs] of genotypes 6, 11, 16, 18 16, 18
Substrate Yeast [S. cerevisiae] Baculovirus expression system
Adjuvant Proprietary aluminium hydroxyphosphate 
sulfate (225µg)
(Merck aluminium adjuvant)
Proprietary aluminium hydroxide (500 µg) plus
50 µg 3-deacylated monophosphoryl lipid A 
(GSK AS04 adjuvant)
Schedule used in trials:
3 intramuscular doses of 0.5 ml with 
intervals of:
Two months between doses 1 and 2;
six months between doses 1 and 3
One month between doses 1 and 2;
six months between doses 1 and 3
Countries/regions included in phase II trials Brazil (34%); Europe (21%); USA (45%) Brazil and North America (over 50% of 
women were from Brazil)
Countries/regions included in phase III trials N. America (25%); Latin America (27%); 
Europe (44%): Asia-Pacific (4%)
N. America (12%); Latin America (34%); 
Europe (30%); Asia-Pacific (25%)
Adolescent safety/immunogenicity bridging 
trials
Females and males 9–15 years Females 10–14 years
Males 10–18 years
Other trials in progress or due to start Efficacy, immunogenicity bridging and safety 
studies in women 25–45 years;
studies of administration at the same time 
as other vaccines;
safety and immunogenicity in HIV-infected 
persons and other immunocompromised 
groups;
efficacy study in males
Efficacy, immunogenicity bridging and safety 
studies in women > 26 years;
studies of administration at the same time as 
other vaccines;
safety and immunogenicity in African 
populations, including HIV-infected women
(VLP) produced by recombinant tech-
nology.29,30 They do not contain any live 
biological product or DNA, so they are 
non-infectious. Current HPV vaccines 
are designed to protect against HPV 
16 and 18; the quadrivalent vaccine 
also protects against low-risk genotypes 
6 and 11. Vaccine trials have been 
conducted predominantly in North 
America, Latin America and Europe 
and none have yet been conducted in 
Africa (Table 2).
One month after the third dose of 
HPV vaccine, nearly 100% of women 
aged 15–26 years in trials of either of 
the vaccines have detectable antibody 
to each HPV genotype, levels being 
10–104 times higher than those in 
natural infections.31–33 Antibody levels 
achieved after vaccination are inversely 
related to age. The antibody responses 
to both the hepatitis B vaccine (re-
combinant) and the quadrivalent HPV 
vaccine were similar whether they were 
administered at the same visit or at 
different visits. Studies to evaluate the 
concomitant use of the quadrivalent and 
bivalent vaccines with other vaccines 
commonly given to adolescents, such 
as combined diphtheria, tetanus and 
pertussis vaccine (Tdap) and meningo-
coccal conjugate vaccine are under way. 
The vaccines have not yet been evalu-
ated among persons with HIV, severe 
malnutrition or intercurrent malarial or 
helminth infection.
For vaccine licensure, the endpoint 
of CIN 2/3 OR AIS has been widely 
accepted as a proxy for cervical cancer 
that can be studied feasibly and ethically 
among women. In children or young ado-
lescents, bridging studies are conducted 
by comparing antibody responses in 
younger persons with those in the women 
for whom data on the clinical endpoint of 
CIN 2/3 OR AIS will also be available.
Protection against infection and 
its clinical consequences
For the bivalent vaccine, data in this re-
port are taken from phase II trials, which 
were powered to detect efficacy against 
incident (new) or persistent infection 
with vaccine-type HPV.31,32 (Since writ-
ing this report, data from the phase 
III trials of both vaccines have been 
published, for example see Ault KA; 
Future II Study Group, Lancet 2007; 
369:1861-8 for the quadrivalent vac-
cine and Paavonen et al, Lancet 2007; 
369:2161-70 for the bivalent vaccine.)
For the quadrivalent vaccine, data 
in this report are taken both from 
published phase II trials and from the 
regulatory presentations for the phase 
III trials that evaluated efficacy against 
the clinical endpoints of moderate-severe 
cervical precancer (CIN 2/3 OR AIS), 
genital warts and vaginal and vulvar pre-
cancerous lesions (http://www.fda.gov/
ohrms/dockets/ac/06/briefing/2006-
4222b-index.htm, and http://www.fda.
gov/ohrms/dockets/ac/06/slides/2006-
4222s-index.htm). The primary analyses 
were conducted among women vacci-
nated according to protocol (no major 
deviations) who did not have evidence 
of past or current infection with the 
relevant HPV genotypes included in the 
vaccines until at least one month after 
the third dose.
Both vaccines have demonstrated 
efficacy of over 90% against persistent 
infection due to genotypes 16 or 18 in 
women who received 3 doses of HPV 
vaccine.32,34 For the bivalent vaccine, 
phase II trials showed zero cases of 
16/18-related CIN 2 among 481 vac-
cinated women and five cases among 
470 women in the placebo group, for 
an efficacy of 100% (95% CI:-7.7, 
100).32 For the quadrivalent vaccine, 
Table 3 shows results at a median of 
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1.5 years after vaccination. For CIN 
2/3 or AIS, the results shown are the 
combined results from four trials; for 
the remaining endpoints in the table, 
results are from three trials (007, 013 
and 015) (http://www.fda.gov/ohrms/
dockets/ac/06/briefing/2006-4222b-
index.htm).
HPV vaccines are designed to be 
prophylactic (i.e. to prevent infection 
and consequent disease). Data on ef-
ficacy, immunogenicity and safety in 
women who have already been exposed 
to vaccine-type HPV are only available 
for the quadrivalent vaccine. Overall, 
no protective effect against CIN 2/3 
OR AIS was seen among women who 
had already been infected with HPV 16 
and 18 before vaccination (http://www.
fda.gov/ohrms/dockets/ac/06/briefing/ 
2006-4222b-index.htm).
Among all women enrolled in the 
trials (including those not vaccinated ac-
cording to protocol and those with base-
line evidence of past or current HPV 
infection), the observed efficacy against 
CIN 2/3 OR AIS was much lower than 
among the women with no evidence 
of past HPV infection. Nonetheless, 
because only a very small minority of 
women had already been infected with 
all four HPV vaccine-types at baseline, 
based on the possible efficacy for other 
vaccine types in women already infected 
with one vaccine-related type, it is not 
necessary to screen for HPV before vac-
cinating women.
Although screening is not needed 
to decide on eligibility for vaccination, 
screening will still be needed among vac-
cinated women, e.g. these women will 
continue to be at risk of infection with 
other types of HPV that can cause CIN 
lesions and cervical cancer.
Cross-protection against other 
genotypes
In preliminary analyses, both vaccines 
have shown some evidence of cross-
protection against HPV 31 and HPV 
45, closely related HPV types to HPV 
16 and 18, respectively. In the extended 
follow-up of the phase II trials of the 
bivalent vaccine, a significant reduc-
tion was found in incident infection 
with type 45 (1 case in 528 vaccinated 
women and 17 cases in 518 controls; 
vaccine efficiency (VE) = 94.2% [63.3, 
99.9]) and type 31 (14 versus 30 cases, 
respectively; VE = 54.5% [11.5, 77.7])32 
For the quadrivalent vaccine, a study of 
ten vaccine recipients in the phase II trial 
who were seronegative and HPV DNA 
negative at baseline for HPV 6, 11, 16, 
18, 31 and 45 showed that serum anti-
bodies from 10 of 10 women neutralized 
HPV 18 pseudovirions, six out of 10 
neutralized HPV type 45 pseudovirions 
and eight out of 10 neutralized HPV 
type 31 pseudovirions.35
For cross-protection to be clinically 
meaningful, it will be necessary to dem-
onstrate that administration of HPV 
vaccines reduces the incidence of persis-
tent HPV infection and biopsy-proven 
CIN caused by HPV types related to 
HPV 16 and HPV 18. Studies are con-
tinuing for both vaccines.
Duration of protection
Antibody levels fall by about one log 
between the peak after the third dose 
and 18 months after vaccination and 
then level off, and have remained as high 
or higher than those seen after natural 
infection for the approximately 5 years 
of follow-up analysed to date.32,36,37 Note 
that the minimum protective antibody 
Table 3. Efficacy of the quadrivalent vaccine against clinical endpoints among women aged 16–26 years (mean 20) in the per 
protocol efficacy populationa
Clinical endpoint Vaccine Placebo Vaccine efficacy % 
(95% CI)
No. of women No. of cases No. of women No. of cases
HPV 16/18-related CIN 2/3 OR AIS 8 487 0 8 460 53 100% (92.9, 100)
HPV 6/11/16/18-related VIN 2/3 7 897 0 7 899 8 100% (41.4, 100)
HPV 6/11/16/18-related VaIN 2/3 7 897 0 7 899 5 100% (< 0, 100)
HPV 6/11/16/18-related genital warts 
(condyloma)
7 897 1 7 899 91 98.9% (93.7, 100)
CI, confidence interval. 
a  Consists of individuals who received all 3 vaccinations within 1 year of enrolment, did not have major deviations from the study protocol, and were naïve (PCR 
negative in cervicovaginal specimens and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and through 1 month Post-dose 3 
(Month 7).
Source: http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4222s-index.htm, FDA presentation, slides 31 and 48.
threshold for disease protection is not 
known. Early results from the quadri-
valent vaccine trials show an increase in 
antibody titres to a challenge dose given 
five years after initial vaccination.37
Protection against persistent infec-
tion32 or a combined endpoint of persis-
tent infection and all genital diseases36 
has been demonstrated for up to 5 years 
post-enrollment in phase II studies, the 
longest reported follow-up so far. Follow-
up studies are planned for both vac-
cines to determine duration of antibody 
and clinical protection among women 
through at least 14 years after dose 3.
Adverse events
For the quadrivalent vaccine, detailed 
safety data reviewed by the US Food and 
Drug Administration are included in the 
label and are available at http://www.
gardasil.com/. Injection site pain, ery-
thema and oedema were common and 
occurred significantly more often for 
vaccine recipients than placebo recipi-
ents. Few subjects (0.1%) discontinued 
due to adverse experiences. Overall, there 
were no differences in the proportion 
of women developing a serious adverse 
event in the vaccine or placebo group. A 
detailed post-licensure plan is in place 
to obtain additional safety data.
Cost-effectiveness of HPV 
vaccine
Knowledge of the burden of disease, 
safety and effectiveness of HPV vaccine 
is not enough to decide whether to 
introduce HPV vaccine. The estimated 
costs of and benefits from HPV vaccine 
need to be compared to those of other 
interventions. The magnitude of benefit 
in a specific country will depend on 
the incidence, mortality and treatment 
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costs of disease attributable to the HPV 
genotypes against which the vaccines 
protect, as well as on the vaccine effi-
cacy, achievable coverage and duration 
of protection.38
Cervical cancer is estimated to cause 
91% of HPV-related cancer deaths, and 
its control is a high priority globally. In 
countries where the treatment of other 
HPV-associated conditions (e.g. genital 
warts, recurrent respiratory papilloma-
tosis and other HPV-related cancers) is 
costly, there may also be substantial cost 
savings from avoidance of these condi-
tions.39 In addition, the time from vac-
cination to prevention of genital warts is 
much shorter than that to cancer.40
In countries with limited or no 
screening and low access to treatment, 
the major predicted benefit from HPV 
vaccination is the potential reduction 
in cervical cancer deaths. Preliminary 
results from cost-effectiveness models 
in low- and middle-income countries 
suggest that a combination of HPV vac-
cination and screening 1–3 times per 
lifetime can be cost-effective for cervi-
cal cancer prevention,41 though not at 
current vaccine prices. Further work is 
needed to assess how robust this finding 
is in different settings.
The coverage that is achievable with 
three doses of HPV vaccine among 
pre-adolescent girls is the major deter-
minant of overall programme effective-
ness. Modelling is ongoing to estimate 
the potential added benefits and costs 
from including older women and/or 
males in vaccination programmes. Direct 
protection of the individual is expected 
to decline as age at vaccination increases, 
as older women will be more likely to 
have had prior HPV infection. Catch-up 
campaigns may shorten the time until 
impact is seen on disease outcomes. The 
potential benefits of vaccinating males 
may include direct protection against 
certain HPV-related conditions and in-
direct protection of women by reducing 
transmission of HPV. Results of dy-
namic simulation models of HPV trans-
mission suggest that if high coverage of 
females can be achieved, there is little 
additional reduction in cervical cancer 
to be gained by vaccinating males.42,43 
At lower coverage, vaccination of boys 
may contribute to controlling infec-
tion, but because vaccination directly 
protects women from cervical cancer, 
more gains may be derived per addi-
tional girl vaccinated than per boy vac-
cinated. Validation of predictions based 
on these complex models will require 
long-term field implementation studies. 
Furthermore, the potential acceptability 
and coverage of a strategy targeting girls 
only against one including both sexes 
should also be considered.
The current price of the quadriva-
lent vaccine is over $100 per dose (with 
three doses recommended to achieve 
full protection). Manufacturers have 
declared their willingness to tier prices 
for countries with different economic 
settings. Vaccine price is likely to be a 
major determinant of the cost and af-
fordability of any vaccine programme. 
Administration costs are expected to 
be higher than for traditional vaccines, 
since very few countries have universal 
programmes for delivering health care 
to pre-adolescents.44
Conclusions
In developing countries, cervical cancer 
is the leading cause of cancer death in 
women, and 91% of global estimated 
HPV-related cancer deaths are due to 
cervical cancer. HPV vaccines are very 
effective at preventing infection and 
disease related to the vaccine-specific 
genotypes in women with no evidence of 
past or current HPV infection. Protec-
tion lasts for at least 5 years. Data are not 
yet available on the safety and efficacy of 
HPV vaccines in Africa, nor in popula-
tions with high HIV prevalence. HPV 
vaccines will reduce but not eliminate 
the risk of cervical cancer, and screening 
programmes will be important interven-
tions for cervical cancer even after HPV 
vaccines are introduced, although the 
procedures used for screening may need 
to be adapted.45
The primary target age group for 
HPV vaccines is likely to be pre-ado-
lescent girls, but the cost-effectiveness 
of vaccinating other groups needs to be 
evaluated. Further data on regional and 
country variations in HPV epidemiol-
ogy, the natural history and transmission 
of HPV infection, the mechanism and 
duration of protection by HPV vaccines, 
whether cross-protection is confirmed 
and the costs and effectiveness of dif-
ferent strategies for vaccination and 
screening will improve predictions of 
the benefits of these new vaccines.46,47 
If a two-dose schedule could be used or 
vaccination could be given at an earlier 
age when other vaccines are given (e.g. 
school-entry or even infancy), vaccine 
delivery could be greatly facilitated, 
and evaluation of these options is ur-
gently required. Innovative methods 
will be needed to finance HPV vaccine 
introduction.48 The potential future 
introduction of HPV vaccines creates 
opportunities for strengthening health 
systems by rapidly establishing new part-
nerships for vaccine delivery, financing 
and monitoring of impacts.49  O
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El cáncer cervicouterino, el más frecuente en mujeres de los 
países en desarrollo, es causado por la infección persistente por 
papilomavirus humanos (PVH) de los genotipos llamados de alto 
riesgo. Los genotipos oncogénicos más frecuentes son el 16 y 
el 18, que causan aproximadamente un 70% de los cánceres 
cervicouterinos. Los tipos 6 y 11 no contribuyen a la incidencia 
de las displasias de alto grado (lesiones precancerosas) ni del 
cáncer cervicouterino, pero causan papilomas laríngeos y la 
mayoría de las verrugas genitales. Los PVH son muy transmisibles 
y su incidencia máxima se registra poco después del inicio de la 
actividad sexual.
Recientemente se ha aprobado en varios países una vacuna 
anti-PVH tetravalente (contra los tipos 6, 11, 16 y 18), después 
de que se haya demostrado que presenta una relación aceptable 
entre los riesgos y los beneficios. En los ensayos clínicos de fase III 
a gran escala, la vacuna evitó el 100% de las lesiones cervicales 
precancerosas moderadas y graves asociadas a los tipos 16 y 18 
en mujeres no infectadas previamente por estos tipos de PVH. 
También se ha evaluado exhaustivamente una vacuna bivalente 
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(contra los tipos 16 y 18) que ha sido aprobada al menos en un 
país. Ambas vacunas está preparadas con partículas no infecciosas, 
carentes de DNA, similares a los virus, producidas mediante 
técnicas de recombinación y combinadas con un adyuvante. Tras 
la administración de tres dosis, inducen concentraciones elevadas 
de anticuerpos séricos en prácticamente todas las personas 
vacunadas. En las mujeres sin infección pasada ni actual por los 
genotipos de PVH presentes en esas vacunas, ambas proporcionan 
una protección > 90% frente a la infección persistente por PVH 
durante periodos de hasta 5 años tras la vacunación (el máximo 
tiempo de seguimiento en los estudios realizados). El mayor 
impacto debería obtenerse con la vacunación de las mujeres 
antes de la edad de exposición a los PVH. Como las vacunas 
anti-PVH no eliminan el riesgo de cáncer cervicouterino, siguen 
siendo necesarias pruebas de detección de esta neoplasia para 
reducir al mínimo su incidencia. Los precios diferenciales de las 
vacunas anti-PVH, los mecanismos de financiación innovadores y 
las alianzas pluridisciplinarias serán esenciales para hacer llegar 
estas vacunas a las poblaciones que más las necesitan.
Résumé
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Le cancer du col utérin, forme la plus courante de cancer chez les 
femmes des pays en développement, est due à l’infection persistante 
par des génotypes « à haut risque » du virus du papillome humain 
(PVH). Les génotypes à risque oncogène les plus courants du PVH 
sont les types 16 et 18, qui sont à l’origine d’environ 70 % des 
cancers du col utérin. Les types 6 et 11 ne contribuent pas à 
l’incidence des dysplasies de haut grade (lésions précancéreuses) 
ou des cancers du col, mais sont la cause de papillomes laryngés 
et de la plupart des condylomes acuminés. Le VPH est hautement 
transmissible et présente un pic d’incidence immédiatement après 
le début de l’activité sexuelle des individus.
Un vaccin anti-VPH quadrivalent (contre les types 6, 11, 
16 et 18) a été récemment autorisé dans plusieurs pays après 
confirmation de l’acceptabilité de son profil risque/bénéfice. Dans le 
cadre d’essais de phase III de grande ampleur, le vaccin a prévenu 
100 % des lésions cervicales précancéreuses de gravité modérée 
et forte associées aux types 16 et 18 chez les femmes exemptes 
au départ d’infection par ces génotypes. Un vaccin bivalent (contre 
les types 16 et 18) a aussi fait l’objet d’une évaluation complète 
et a été autorisé dans un pays au moins. Ces deux vaccins sont 
préparés à partir de particules pseudo-virales dépourvues d’ADN 
et non-infectieuses, produites par génie génétique et associées 
à un adjuvant. Après administration en trois doses, ils induisent 
la production de titres d’anticorps sériques élevés chez presque 
tous les individus vaccinés. Chez les femmes ne présentant aucun 
indice d’infection antérieure ou actuelle par des VPH appartenant 
aux génotypes vaccinaux, ils apportent tous deux une protection 
de plus de 90 % contre les infections à VPH persistantes sur une 
période postvaccinale allant jusqu’à 5 ans (qui est aussi la plus 
longue durée de suivi rapportée à ce jour). L’effet de la vaccination 
devrait être maximal si l’on vaccine la population féminine avant 
qu’elle soit exposée aux VPH. Les vaccins anti-VPH n’éliminant 
pas le risque de cancer du col utérin, les examens de dépistage 
de ce cancer resteront nécessaires pour réduire au minimum son 
incidence. Pour que ces vaccins atteignent les populations qui en 
ont le plus besoin, il est extrêmement important de mettre en place 
une gradation des prix, des mécanismes de financement innovants 
et des partenariats multidisciplinaires.
صخلم
هتاحاقلو يشربلا يميلُحلا مرولا سويرفل ضارعتسا
 ثانلإا ينب ناطسرلل ًاعويش ثركلأا طمنلا دعُي يذلا ،محرلا قنع ناطسر مجني
 سويرفب راطتخلاا ةيلاع ةينيج طانمأب ةيمدتسم ىودع نع ،ةيمانلا نادلبلا في
 طانملأا ثركأ سويرفلا نم 18 و 16 ناطمنلا برتعُيو .يشربلا يميلُحلا مرولا
 ةباصلإا تلااح عيمج نم %70 وحن في ناببستي ذإ ،ًاعويش ةنطسرلما ةينيجلا
 ج ُّسنتلا للخ ثودح في نماهسي لاف 11و 6 ناطمنلا امأ .محرلا قنع ناطسرب
 ناببسي نكلو ،محرلا قنع ناطسر وأ )نُطسرتلل ةقباسلا تافلآا( ةجردلا لياعلا
 سويرف زيمتيو .ةيلسانتلا ةيلولؤثلا ضارملأا مظعمو ةرجنحلل ةيميلحلا مارولأا
 دعب هعوقو ةورذ ثدحتو ،ةياسرلا لىع ةيلاع ةردقب يشربلا يميلحلا مرولا
.ًةشرابم سينجلا طاشنلا ءدب
 مرولا  سويرف  دض  ؤفاكتلا  يعابر  حاقل  مادختساب  صيخرـتلا  مت  دقو
 نأ تبث نأ دعب ،نادلبلا نم ددع في )18،16،11،6 طانملأل( يشربلا يميلُحلا
 ،ةثلاثلا ةلحرلما براجت يفف .ةلوبقلما دودحلا في عقت هرطاخمو هدئاوف لمجم
 ةديدشلاو  ةطسوتلما  محرلا  قنع  تافآ  نم  %100  ءاقِّتا  في  حاقللا  حجن
 تيلالا تاديسلا ينب كلذو ،18  و 16  ينطمنلاب ةطبترلماو نُطسرتلل ةقباسلا
 ؤفاكتلا  ئيانث  حاقل  عضخ ماك .ينطمنلا  نيذهب  ىودعلاب  نهتباصإ  قبست  لم
 دلب  في  هلماعتساب  ص ِّخُرو  قاطنلا  عساو  ميـيقتل  )18  و  16  ينطمنلا  نم(
 ةهيبش ،ةيدعم يرغ تمايسج نم هيرضحت مت ينحاقللا لاكو .لقلأا لىع دحاو
 تابوشألما ايجولونكتب اهجاتنإ مت ،DNA اندلا ضمح نم ةيلاخو سويرفلاب
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 لىإ  ينحاقللا  نم  تاعرج ثلاث  ءاطعإ  يدؤيو  .دعاسم لماع  اهيلإ  فيضُأو
 حاقللا او ُّقلت نيذلا دارفلأا عيمج في لصلما دادضأ نم ةيلاع تايوتسم جاتنإ
 وأ  ةقباس  ىودعب  نهتباصإ  لىع  تانِّيب  دجوت  لا  يتلا  تاديسلا  امأ  .ًابيرقت
 ،حاقللا  في ةدوجولما يشربلا يميلُحلا  مرولا سويرفل ةينيجلا طانملأاب ةيلاح
 سويرفلاب ةيمدتسلما ىودعلا دض %90 لىع ديزت ةياقو ناحاقللا نهحنم دقف
 .نلآا ىتح ةعباتم ةدم لوطأ يهو ،ميعطتلا دعب تاونس 5 لىإ لصت ةدلم
 هل  نوكي  دق  سويرفلل  ثانلإا  ضُّرعت  قبسي  نس  في  ميعطتلا  نأ  ظحولو
 لىع ضيقت لا يشربلا  يميلُحلا  مرولا  سويرف تاحاقل  نلأ  ًارظنو .رثلأا  بركأ
 صحف ةلصاوم رملأا يعدتسي فوسف ،محرلا قنع ناطسرب ةباصلإا رطاخم
 رملأا مزلتسيس ماك .ناكملإا ردق ناطسرلا عوقو نم دحلا ةيغب ،محرلا قنع
 ةركتبم تايلآ ذاخِّتاو ،يميلُحلا مرولا سويرف تاحاقلل ةتوافتم راعسأ ديدحت
 لىإ تاحاقللا لوصو نماضل ،تاص ُّصختلا ةددعتم تاكاشر ةماقإو ،ليومتلل
.اهيلإ ًاجايتحا دشلأا ةيناكسلا تائفلا
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